55 completed, 22 unknown, 11 active not recruiting, 10 terminated. 35 Phase 2, 26 Not applicable, 19 Phase 1, 9 Phase 3, 3 Phase 4.
Follow NASH - Nonalcoholic Steatohepatitis: new trials by email Literature Review of NASH - Nonalcoholic Steatohepatitis trials Research Report on NASH - Nonalcoholic Steatohepatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis SNP-610, Placebo Oral Tablet - NASH - Nonalcoholic Steatohepatitis | Phase 2 | Not yet recruiting | Sinew Pharma Inc. | 80 | 2026-04-01 | 2026-03-18 |
| Digital Therapeutic Lifestyle Intervention Program for Patients With MASLD Noom Weight Application - NASH, NASH - Nonalcoholic Steatohepatitis | Not applicable | Withdrawn | Milton S. Hershey Medical Center | 2025-09-01 | 2025-07-25 | |
| A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH Efruxifermin, Placebo - NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis | Phase 3 | Recruiting | Akero Therapeutics, Inc | 2150 | 2024-10-04 | 2026-10-13 |
| Integrated Phenotyping of the Gut-plAtelet-Liver AXIS in the Progression of Chronic Liver Disease (iGAL-AXIS) Platelets characterization - Non-alcoholic Fatty Liver Disease (NAFLD), NASH - Nonalcoholic Steatohepatitis | Unknown | Stefania Basili | 132 | 2024-09-30 | 2024-10-04 | |
| Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis Exercise Intervention with use of El-Fit App - NASH - Nonalcoholic Steatohepatitis, NASH | Not applicable | Completed | Milton S. Hershey Medical Center | 17 | 2024-02-01 | 2026-04-08 |
| Development and Validation of a Multi-target, Blood-based NAFLD Diagnosis Test NAFLD, NASH - Nonalcoholic Steatohepatitis | Unknown | HBI Solutions Inc. | 1500 | 2023-05-01 | 2023-03-23 | |
| Statins for the Treatment of NASH Atorvastatin, Placebo - NASH - Nonalcoholic Steatohepatitis | Phase 2 | Active not recruiting | Mayo Clinic | 70 | 2023-01-25 | 2026-01-20 |
| Interest in "Combo" (a Combination of Dietary Supplements Including Probiotics) in NASH Improvement Treatment with Combo, Treatment with placebo - NASH - Nonalcoholic Steatohepatitis | Not applicable | Unknown | Mativa-Tech SA | 60 | 2023-01-01 | 2023-11-07 |
| Semaglutide vs Sitagliptin Semaglutide Treatment, Sitagliptin 100mg - Liver Transplant; Complications, Diabetes Mellitus | Phase 4 | Active not recruiting | University Health Network, Toronto | 58 | 2022-10-26 | 2026-10-14 |
| Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH Ultrasound liver assessment - Liver Diseases, Liver Cirrhosis | Not applicable | Unknown | E-Scopics | 1000 | 2022-09-01 | 2022-08-23 |
| The Franciscus Obesity NASH Study NASH screening, Cardiac dysfunction screening, Liver biopsy - NAFLD, NASH - Nonalcoholic Steatohepatitis | Active not recruiting | Franciscus Gasthuis | 300 | 2022-09-01 | 2025-08-27 | |
| The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease LUM-201 - NAFLD, Nonalcoholic Fatty Liver | Phase 2 | Completed | Massachusetts General Hospital | 12 | 2022-08-10 | 2026-01-06 |
| Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus Lanifibranor, Placebo, Empagliflozin - NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2 | Phase 2 | Completed | Inventiva Pharma | 39 | 2022-06-29 | 2026-09-09 |
| DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis TERN-501, TERN-101, Placebo - NASH - Nonalcoholic Steatohepatitis | Phase 2 | Completed | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 162 | 2022-06-28 | 2025-03-12 |
| A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH MSDC-0602K, Placebo - Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis | Phase 3 | Unknown | Cirius Therapeutics, Inc. | 1800 | 2022-06-01 | 2021-07-12 |
| Nonalcoholic Fatty Liver Disease in HIV Database NAFLD, NASH - Nonalcoholic Steatohepatitis | Active not recruiting | Johns Hopkins University | 400 | 2022-05-12 | 2026-01-15 | |
| Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity Bariatric surgery - Obesity, Morbid, NASH - Nonalcoholic Steatohepatitis | Recruiting | Mayo Clinic | 60 | 2022-02-20 | 2026-01-28 | |
| Pentoxifylline in Treatment of Patients With Nonalcoholic Steatohepatitis pentoxifylline (Trental SR®) - NASH - Nonalcoholic Steatohepatitis | Phase 3 | Completed | Al-Azhar University | 50 | 2022-02-01 | 2024-06-21 |
| Novel MRE Technique to Assess a Risk Factor for Liver Cancer NASH - Nonalcoholic Steatohepatitis | Active not recruiting | Natalie Torok | 35 | 2022-01-27 | 2026-04-23 | |
| Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) Namodenoson, Placebo - NASH - Nonalcoholic Steatohepatitis | Phase 2 | Unknown | Can-Fite BioPharma | 114 | 2021-12-10 | 2024-07-31 |
Showing 20 of 114. Sign in to see all of them.
Non-alcoholic Fatty Liver Disease (114) · Fatty Liver (15) · Fibrosis (12) · Liver Cirrhosis (10) · Obesity (10) · Diabetes Mellitus, Type 2 (8) · Obesity, Morbid (6) · Diabetes Mellitus (5) · Liver Diseases (5) · Metabolic Syndrome (4) · Carcinoma, Hepatocellular (3) · Hepatitis (3) · Insulin Resistance (3) · Acquired Immunodeficiency Syndrome (2) · Dyslipidemias (2)
Digestive System Diseases (113) · Liver Diseases (109) · Fatty Liver (99) · Pathological Conditions, Signs and Symptoms (31) · Nutritional and Metabolic Diseases (28) · Pathologic Processes (22) · Metabolic Diseases (19) · Glucose Metabolism Disorders (18) · Signs and Symptoms (14) · Endocrine System Diseases (13) · Body Weight (12) · Nutrition Disorders (12) · Overnutrition (12) · Overweight (10) · Diabetes Mellitus (8)
Bariatric Surgery (3) · EDP-305 (3) · empagliflozin (3) · Atorvastatin (2) · Elasticity Imaging Techniques (2) · Ethinyl Estradiol (2) · lanifibranor (2) · resmetirom (2) · (2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2H-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid (1) · 2-((3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy)methyl)-4-(3-chlorophenyl)-2-oxido(1,3,2)dioxaphosphonane (1) · 2-chloro-3-(1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-6-oxo-5-phenyl-7H-thieno)(2,3-b)pyridin-4-olate potassium (1) · 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide (1) · 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (1) · ALT-801 (1) · Biopsy (1)
Akero Therapeutics, Inc (4) · Enanta Pharmaceuticals, Inc (4) · Indiana University (3) · Milton S. Hershey Medical Center (3) · Rivus Pharmaceuticals, Inc. (3) · Sinew Pharma Inc. (3) · Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (3) · 89bio, Inc. (2) · Assistance Publique - Hôpitaux de Paris (2) · Catholic University of the Sacred Heart (2) · Cirius Therapeutics, Inc. (2) · Erasme University Hospital (2) · Inventiva Pharma (2) · Johns Hopkins University (2) · Maastricht University Medical Center (2)
United States (61) · France (17) · Puerto Rico (11) · Belgium (10) · Italy (10) · United Kingdom (10) · Germany (9) · Spain (8) · Australia (7) · Netherlands (7) · Canada (6) · Israel (6) · Mexico (6) · Poland (5) · Argentina (4)
Raj Vuppalanchi, M.D. (2) · Samer Gawrieh, MD (2) · Adel Gaber Bakr, PhD (1) · Ahmed ElGhandour, MD (1) · Amal Ahmed, PhD (1) · Amy Eastenson (1) · Amy Eastenson, MD (1) · Andrea Branch, PhD (1) · Andrew Wheeler, MD (1) · Anthony DelConte (1) · Arun J Sanyal, MD (1) · Arun Sanyal, M.D. (1)
PMID 39326675, PMID 22913681, PMID 30224284, PMID 31697972, PMID 33104014, PMID 33793651, PMID 33860116, PMID 34239138, PMID 35325622, PMID 35434590, PMID 35596633, PMID 35820779, PMID 36644237, PMID 37356033, PMID 37400234, PMID 37696614, PMID 37786277, PMID 37806314, PMID 38324483, PMID 38447814, PMID 38462919, PMID 38901559, PMID 39131144, PMID 39250515, PMID 39402603, PMID 40341827, PMID 40500414, PMID 40818852, PMID 41127972, PMID 41438070, PMID 41895606, PMID 41969201, PMID 42817874
2018 (2), R01DK121378 (1), R01DK124417 (1), R01DK126955 (1), U01OH011489 (1)